Table 3 PFS for patients receiving dostarlimab + chemotherapy and pembrolizumab + chemotherapy (ITT population as of August 4, 2022)

From: Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell lung cancer: the randomized PERLA phase II trial

Variable

Dostarlimab + chemotherapy (N = 121)

Pembrolizumab + chemotherapy (N = 122)

Median PFS follow-up time, months (IQR)

9.1 (6.8–11.4)

9.0 (6.7–11.2)

PFS events observed, n

64

74

Median PFS (95% CI), months

8.8 (6.7–10.4)

6.7 (4.9–7.1)

Estimated probability of PFS, % (95% CI)

  6 months

61 (52–70)

52 (42–61)

  9 months

46 (36–56)

36 (26–45)

Hazard ratio (95% CI)

0.70 (0.50–0.98)

  1. PFS was assessed per RECIST v1.1 based on investigator assessment.
  2. CI confidence interval, IQR interquartile range, ITT intention-to-treat, PFS progression-free survival, RECIST v1.1 Response Evaluation Criteria in Solid Tumors version 1.1.
Back to article page